Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

Jennifer C.E.Lane, James Weaver, Kristin Kostka, Talita Duarte-Salles, Maria Tereza F. Abrahao, Heba Alghoul, Osaid Alser, Thamir M Alshammari, Patricia Biedermann, Edward Burn, Paula Casajust, Mitch Conover, Aedin C. Culhane, Alexander Davydov, Scott L. DuVall, Dmitry Dymshyts, Sergio Fernandez-Bertolin, Kristina Fišter, Jill Hardin, Laura Hester, George Hripcsak, Seamus Kent, Sajan Khosla, Spyros Kolovos, Christophe G. Lambert, Johan van der Lei, Ajit A. Londhe, Kristine E. Lynch, Rupa Makadia, Andrea V. Margulis, Michael E. Matheny, Paras Mehta, Daniel R. Morales, Henry Morgan-Stewart, Mees Mosseveld, Danielle Newby, Fredrik Nyberg, Anna Ostropolets, Rae Woong Park, Albert Prats-Uribe, Gowtham A. Rao, Christian Reich, Jenna Reps, Peter Rijnbeek, Selva Muthu Kumaran Sathappan, Martijn Schuemie, Sarah Seager, Anthony Sena, Azza Shoaibi, Matthew Spotnitz, Marc A. Suchard, Joel Swerdel, Carmen O. Torre, David Vizcaya, Haini Wen, Marcel de Wilde, Seng Chan You, Lin Zhang, Oleg Zhuk, Patrick Ryan, Daniel Prieto-Alhambra on behalf of OHDSI-COVID-19 consortium.
doi: https://doi.org/10.1101/2020.04.08.20054551

Article Information

doi 
https://doi.org/10.1101/2020.04.08.20054551
History 
  • April 10, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Jennifer C.E.Lane, MRCS*,1,
  2. James Weaver, MSc*,2,
  3. Kristin Kostka, MPH3,
  4. Talita Duarte-Salles, PhD4,
  5. Maria Tereza F. Abrahao, PhD5,
  6. Heba Alghoul, MD6,
  7. Osaid Alser, MD7,
  8. Thamir M Alshammari, PhD8,
  9. Patricia Biedermann, MSc9,
  10. Edward Burn, MSc1,4,
  11. Paula Casajust, MSc10,
  12. Mitch Conover2,
  13. Aedin C. Culhane, PhD11,
  14. Alexander Davydov, MD12,
  15. Scott L. DuVall, PhD13,14,
  16. Dmitry Dymshyts, MD12,
  17. Sergio Fernandez-Bertolin, MSc2,
  18. Kristina Fišter, MD15,
  19. Jill Hardin, PhD2,
  20. Laura Hester, PhD2,
  21. George Hripcsak, MD16,17,
  22. Seamus Kent, PhD18,
  23. Sajan Khosla, MSc19,
  24. Spyros Kolovos, PhD1,
  25. Christophe G. Lambert, PhD20,
  26. Johan van der Lei, PhD21,
  27. Ajit A. Londhe, MPH22,
  28. Kristine E. Lynch, PhD13,14,
  29. Rupa Makadia, PhD2,
  30. Andrea V. Margulis, ScD23,
  31. Michael E. Matheny, MD13,24,
  32. Paras Mehta, BA25,
  33. Daniel R. Morales, PhD26,
  34. Henry Morgan-Stewart, PhD3,
  35. Mees Mosseveld, MSc21,
  36. Danielle Newby, PhD27,
  37. Fredrik Nyberg, PhD28,
  38. Anna Ostropolets, MD16,
  39. Rae Woong Park, MD29,
  40. Albert Prats-Uribe, MPH1,
  41. Gowtham A. Rao, MD2,
  42. Christian Reich, MD3,
  43. Jenna Reps, PhD2,
  44. Peter Rijnbeek, PhD21,
  45. Selva Muthu Kumaran Sathappan, MSc30,
  46. Martijn Schuemie, PhD2,
  47. Sarah Seager, BA3,
  48. Anthony Sena2,
  49. Azza Shoaibi, PhD2,
  50. Matthew Spotnitz, MD16,
  51. Marc A. Suchard, MD31,
  52. Joel Swerdel, PhD2,
  53. Carmen O. Torre, MSc3,
  54. David Vizcaya, PhD32,
  55. Haini Wen, MSc33,
  56. Marcel de Wilde, BSc21,
  57. Seng Chan You, MD29,
  58. Lin Zhang, MD34,
  59. Oleg Zhuk, MD12,
  60. Patrick Ryan, PhD2,**,
  61. Daniel Prieto-Alhambra, PhD1,4 and
  62. on behalf of OHDSI-COVID-19 consortium.
  1. 1Centre for Statistics in Medicine, NDORMS, University of Oxford
  2. 2Janssen Research and Development, Titusville, NJ, USA
  3. 3Real World Solution, IQVIA, Cambridge, MA, USA
  4. 4Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
  5. 5Faculty of Medicine, University of Sao Paulo, Brazil
  6. 6Faculty of Medicine, Islamic University of Gaza
  7. 7Massachusetts General Hospital, Harvard Medical School, Boston, USA
  8. 8King Saud University, Riyadh, Saudi Arabia
  9. 9Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
  10. 10Real-World Evidence, Trial Form Support, Barcelona, Spain
  11. 11Department of Data Sciences, Dana-Farber Cancer Institute, Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA
  12. 12Medical Ontology solutions, Odysseus Data Services Inc, Cambridge MA
  13. 13Department of Veterans Affairs, USA
  14. 14University of Utah School of Medicine, USA
  15. 15University of Zagreb, School of Medicine, Andrija Štampar School of Public Health
  16. 16Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA
  17. 17NewYork-Presbyterian Hospital, New York, NY, USA
  18. 18National Institute for Health and Care Excellence, UK
  19. 19AstraZeneca, Real World Science & Digital, Cambridge UK
  20. 20Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
  21. 21Erasmus MC, Rotterdam, Netherlands
  22. 22Amgen, Center for Observational Research, Thousand Oaks, CA USA
  23. 23RTI Health Solutions, Buenos Aires, Argentina
  24. 24Vanderbilt University, USA
  25. 25College of Medicine, University of Arizona, USA
  26. 26Division of Population Health and Genomics, University of Dundee, Scotland, UK
  27. 27University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford UK
  28. 28Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  29. 29Department of Biomedical Informatics, Ajou University, Suwon, South Korea
  30. 30Saw Swee Hock School of Public Health, National University of Singapore, Singapore
  31. 31Department of Biostatistics, University of California, Los Angeles
  32. 32Bayer pharmaceuticals, Barcelona, Spain
  33. 33Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
  34. 34School of Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences & Melbourne School of Population and Global Health, University of Melbourne
  1. ↵**Corresponding author: Patrick Ryan, Janssen Research & Development, Titusville, NJ, USA ryan{at}ohdsi.org, 919.609.2723

  1. ↵* equal contribution

Back to top
Posted April 10, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Jennifer C.E.Lane, James Weaver, Kristin Kostka, Talita Duarte-Salles, Maria Tereza F. Abrahao, Heba Alghoul, Osaid Alser, Thamir M Alshammari, Patricia Biedermann, Edward Burn, Paula Casajust, Mitch Conover, Aedin C. Culhane, Alexander Davydov, Scott L. DuVall, Dmitry Dymshyts, Sergio Fernandez-Bertolin, Kristina Fišter, Jill Hardin, Laura Hester, George Hripcsak, Seamus Kent, Sajan Khosla, Spyros Kolovos, Christophe G. Lambert, Johan van der Lei, Ajit A. Londhe, Kristine E. Lynch, Rupa Makadia, Andrea V. Margulis, Michael E. Matheny, Paras Mehta, Daniel R. Morales, Henry Morgan-Stewart, Mees Mosseveld, Danielle Newby, Fredrik Nyberg, Anna Ostropolets, Rae Woong Park, Albert Prats-Uribe, Gowtham A. Rao, Christian Reich, Jenna Reps, Peter Rijnbeek, Selva Muthu Kumaran Sathappan, Martijn Schuemie, Sarah Seager, Anthony Sena, Azza Shoaibi, Matthew Spotnitz, Marc A. Suchard, Joel Swerdel, Carmen O. Torre, David Vizcaya, Haini Wen, Marcel de Wilde, Seng Chan You, Lin Zhang, Oleg Zhuk, Patrick Ryan, Daniel Prieto-Alhambra
medRxiv 2020.04.08.20054551; doi: https://doi.org/10.1101/2020.04.08.20054551
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area